Microorganisms and processes for producing L-glutamine

This application is a continuation application of International Application Ser. No. PCT/KR01/01952, filed Nov. 15, 2001 and published as WO 02/40643, which claims priority to Korean Application Serial No. 2000/68284 and Korean Application Ser. No. 2000/68285, both filed Nov. 17, 2000. Said applications are included herein in their entirety by reference.

L-glutamine is an amino acid widely used as medicines such as therapeutic agents of gastroenterologic disorders, potentiators of liver and brain functions, immuno-enhancement agents, and therapeutic agents of gastric ulcer and alcoholism, etc., cosmetics such as moisturizers, etc., and health foods such as sports nutrients and nutrients for patients, etc.

According to the prior art, L-glutamine was obtained from sulfaguanidine-resistant strains (Japanese Patent, Laid-Open No. Sho53-17675), azaserine-resistant strains (Japanese Patent Laid-Open No. Sho55-148094) penicillin-sensitive strains (Japanese Patent Laid-Open No. Hei04-088994), tyrosine-glutamic acid (tyr-glu)-resistant strains (Japanese Patent Laid-Open No. Hei02-186994) and the like.

The present invention relates to novel microorganisms producing L-glutamine and to processes for producing L-glutamine using the same. More specifically, the invention relates to Brevibacterium lactofermentum CJJA21 (KCCM-10222) resistant to sodium azide and Brevibacterium lactofermentum CJJA22 (KCCM-10223) resistant to D,L-α-amino-n-butyric acid: α-ABA), both of which are capable of producing L-glutamine in a higher yield than the known strains, and to processes for producing L-glutamine using the same.

The present inventors performed extensive studies to develop novel strains, which are capable of producing L-glutamine in a high productivity. We contemplated that strains resistant to sodium azide, a respiratory inhibitor, or to α-aminobutyric acid, an analogue of an amino acid, isoleucine, would have the increased productivity of L-glutamine. Thus, we screened sodium azide or α-aminobutyric acid-resistant strains from an original strain, Brevibacterium lactofermentum KFCC-10680 (Korean Patent Publication No. 91-7818). This strain was deposited as KFCC-10680 with the Korean Culture Center of Microorganisms on Oct. 8, 1989 for the purpose of patent procedures and described in Korean Patent No. 91-7818. issued on Oct. 2. 1991. As a result, we identified that the sodium azide- or α-aminobutyric acid-resistant strains produce L-glutamine in a higher yield than the known strains and thus, completed the present invention.

The present invention provides microorganisms producing L-glutamine and processes for producing L-glutamine using the same. The microorganisms according to the present invention are Brevibacterium lactofermentum CJJA21 (KCCM-10222) having a resistance to sodium azide and Brevibacterium lactofermentum CJJA22 (KCCM-10223) having a resistance to α-aminobutyric acid, both of which produce L-glutamine in a high yield. Further, the processes for producing L-glutamine according to the present invention is characterized by the activation of Brevibacterium lactofermentum CJJA21 or Brevibacterium lactofermentum CJJA22 followed by the cultivation of the activated strains.

In the present invention, mutants were induced by the following methods. Brevibacterium lactofermentum KFCC-10680 was treated with N-methyl-N′-nitro-N-nitrosoguanidine (NTG), a conventional mutagen and then, spread on a minimal medium (Medium 1) containing 500 mg/l of sodium azide thereby to obtain strains having a resistance to 500 mg/l of sodium azide.

More specifically, Brevibacterium lactofermentum KFCC-10680, which had been previously activated by cultivation on an activation medium (Medium 2) for 16 hours, was cultivated for 14 hours on a seed medium (Medium 3) sterilized at 121° C. for 15 minutes. Then, 5 mL the culture medium was washed with 100 mM citrate buffer and thereto was added NTG at a final concentration of 200 mg/l. After 20 minutes, the medium was washed with 100 mM phosphate buffer. The strains treated with NTG were spread on a minimal medium (Medium 1) and the death rate was measured. As a result, the death rate was 85%.

In order to obtain sodium azide-resistant mutants, the NTG-treated strains were spread on a minimal medium (Medium 1) containing sodium azide at a final concentration of 500 mg/l and then, cultivated at 30° C. for 6 days to obtain sodium azide-resistant strains. The obtained resistant mutants were cultivated in a shaking Erlenmeyer flask containing a glutamine production medium (Medium 4) for 72 hours thereby to select a sodium azide-resistant strain producing L-glutamine in a 10% or more higher yield than the original strain, Brevibacterium lactofermentum KFCC-10680. The obtained strain was designated as CJJA21. Brevibacterium lactofermentum CJJA21 was deposited under the Budapest Treaty to the Korean Culture Center of Microorganisms whose address is Hongje-dong, Seodaemun-gu, Seoul, on Oct. 20, 2000, with the Accession No. KCCM-10222.

In addition, Brevibacterium lactofermentum KFCC-10680 was activated and cultivated in the substantially same manner as above. It was subsequently treated with NTG in the substantially same manner as above. In order to obtain α-aminobutyric acid-resistant mutants, the NTG treated strains were spread on a minimal medium (Medium 1) containing α-aminobutyric acid at a final concentration of 15 g/l and then, cultivated at 30° C. for 6 days to obtain α-aminobutyric acid-resistant strains. The obtained resistant mutants were cultivated, in a shaking Erlenmeyer flask containing a glutamine production medium (Medium 4) for 72 hours thereby to select a α-aminobutyric acid-resistant strain producing L-glutamine in a 10% or more higher yield than the original strain, Brevibacterium lactofermentum KFCC-10680. The obtained strain was designated as CJJA22. Brevibactertium lactofermentum CJJA22 was deposited under the Budapest Treaty to the Korean Culture Center of Microorganisms whose address is Hongje-dong, Seodaemun-gu, Seoul, on Oct. 20, 2000, with the Accession No. KCCM-10223.

Culture media employed in the present invention have the following compositions:

Medium 1: Minimal medium

Glucose 1.0%, Ammonium Sulfate ((NH 4 ) 2 SO 4 ) 0.4%, Magnesium Sulfate (MgSO 4 7H 2 O) 0.04%, Potassium Dihydrogen Phosphate (KH 2 PO 4 ) 0.1%, Urea 0.1%, Thiamine HCl 0.0001%, Biotin 200 μg/l, Agar, pH 7.0

Medium 2: Activation medium

Beef extract 1%, Polypeptone 1%, Sodium Chloride (NaCl) 0.5%, Yeast Extract 0.5%, Agar 2%, pH 7.2

Medium 3: Seed medium

Glucose 5%, Bactgpeptone 1%, Sodium Chloride (NH 4 Cl) 0.25%, Yeast Extract 1%, Biotin 3 μg/l, Urea 0.4%, pH 7.0

Medium 4: Glutamine production medium

Glucose 4.0%, Ammonium Chloride (NH 4 Cl) 3.0%, Soy Protein Acid Hydrolyzate 0.3%, Calcium Carbonate (CaCO 3 ) 5%, Calcium Chloride (CaCl 2 ) 0.1%, Magnesium Sulfate (MgSO 4 7H 4 O) 0.05%, Potassium Dihydrogen Phosphate (KH 2 PO 4 ) 0.15%, Potassium Monohydrogen Phosphate (K 2 HPO 4 ) 0.15%, Urea 0.3%, Thiamine, HCl 2 mg/l, Biotin 5 μg/l, Ferric Sulfate (FeSO 4 7H 2 O) 20 mg/l, Manganese Sulfate (MnSO 4 H 2 O) 20 mg/l, Zinc Sulfate (ZnSO 4 7H 2 O) 12 mg/l, pH 6.8.

Sodium azide-resistance of Brevibacterium lactofermentum CJJA21 is shown in the following Table 1—1.

α-Aminobutyric acid-resistance of Brevibacterium lactofermentum CJJA22 is shown in Table 1-2.

According to the present invention, L-glutamine can be obtained in a higher yield than the prior art. In some embodiments of the invention, about 10% more L-glutamine, more preferably about 15% more L-glutamine is produced by microorganisms of the invention than by wild-type strains grown under the same conditions. This improvement is illustrated by, inter alia, Examples 1–4. The obtained L-glutamine is useful for medicines such as therapeutic agents of gastroenterologic disorders, potentiators of liver and brain functions, immuno-enhancement agents, therapeutic agents of gastric ulcer and alcoholism, etc., cosmetics such as moisturizers, etc., and health foods such as sports nutrients and nutrients for patients, etc.

This invention will be better understood from the following examples. However, one skilled in the art will readily appreciate the specific materials and results described are merely illustrative of, and are not intended to, nor should be intended to, limit the invention as described more fully in the claims which follows thereafter.